FDA Adds Another Blood Pressure Medicine to Recall

Henrietta Strickland
September 24, 2019

The recall was conducted in coordination with the US Food and Drug Administration (FDA), after finished product batches were manufactured with active pharmaceutical ingredient (API) produced by Hetero Labs - a company involved in previous recalls.

Monday's announcement targets an additional five lots of the generic drug losartan made by Torrent Pharmaceuticals Limited.

The recall includes only the five lots which were found to contain the chemical: three of Losartan Potassium Tablets USP and two of Losartan Potassium/Hydrochlorothiazide Tablets USP.

The substance, called N-Methylnitrosobutyric acid or NMBA, is a "probable human carcinogen", according to the FDA. Losartan Potassium and Hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy. The FDA says patients who take these tablets should continue to do so until you speak with your physician about alternative options. Patients should also contact their doctor about an alternative treatment.

Torrent Pharmaceuticals was one of about six medication organizations that in December 2018 reported an intentional review of losartan potassium tablets in view of follow measures of pollutions found in a functioning pharmaceutical fixing.

Several pharmaceutical companies have recalled blood pressure medications after finding impurities that could cause cancer.

A provided image shows high blood pressure medication under the expanded recall, announced by the FDA.

Other reports by Click Lancashire

Discuss This Article